跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
查看斯高帕斯 (Scopus) 概要
洪 小雅
助理教授
醫學生物技術暨檢驗學系
電話
02-28267167
電子郵件
shaline
nycu.edu
tw
h-index
h10-index
h5-index
334
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
225
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
136
引文
7
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2008
2025
每年研究成果
概覽
指紋
網路
研究成果
(27)
類似的個人檔案
(6)
指紋
查看啟用 Shiao-Ya Hong 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Lung Adenocarcinoma
72%
Tensin
55%
Retrospective Cohort Study
50%
Pulmonary Function
50%
Phosphorylation
50%
E3 Ubiquitin Ligase
50%
RNA Replication
48%
Hepatitis delta Antigen
48%
Boron Neutron Capture Therapy
48%
Biological Efficacy
48%
Vaccination
48%
Enhanced Cancer Therapy
48%
Palbociclib
48%
Statins
48%
Protective Effect
48%
Taiwan
48%
Aurora Kinase A (AURKA)
35%
Hepatitis delta Virus
33%
IgG Levels
32%
Seroconversion Rate
30%
Inflammation
29%
Pancreatic Tumor
29%
Tumorigenicity
28%
Reactogenicity
28%
Cell Proliferation
26%
Expression Pattern
26%
Processive
24%
Uterine Smooth muscle Tumor of Uncertain Malignant Potential
24%
ChAdOx1 nCov-19 Vaccination
24%
Anti-RBD IgG
24%
Anti-spike IgG
24%
Humoral Immunogenicity
24%
SHP-1
24%
Humoral Antibody Response
24%
Lung Squamous Cell Carcinoma
24%
Lipopolysaccharide-induced Inflammation
24%
EGF Receptor
24%
Induced Degradation
24%
Polymerase II
24%
RNA-dependent RNA Polymerase (RdRP)
24%
Tumor Spheroids
24%
Acute Lung Injury
24%
Microfluidic-based
24%
Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitor
24%
Alisertib
24%
Viral
24%
Pulmonary Fibrosis
24%
Macrophages
24%
Allogeneic
24%
Biochemistry, Genetics and Molecular Biology
Tensin
64%
Epidermal Growth Factor Receptor
57%
C-Terminus
54%
Ubiquitin-Conjugating Enzyme
50%
RNA Replication
48%
Hepatitis D
48%
Tumor Spheroid
48%
Serine
48%
Cohort Study
48%
Lung Function
48%
Hyperuricemia
48%
Hyperlipidemia
48%
Statin
48%
Bone Density
48%
Aurora A Kinase
36%
Messenger RNA
34%
Hepatitis Delta Virus
33%
Immunogenicity
32%
Cell Proliferation
30%
Isoform
30%
Seroconversion
30%
Single-Nucleotide Polymorphism
27%
Cancer Cell
27%
Fibroblast
26%
Downregulation
24%
RNA Polymerase
24%
Mesenchymal-Epithelial Transition
24%
Antibody Response
24%
Phylogeny
24%
Receptor Tyrosine Kinase Inhibitors
24%
Spike
24%
Growth Factor Receptor
24%
Expression Analysis
24%
Hemodialysis
24%
Upregulation
24%
Promoter Region
24%
Cladistics
24%
Genetic Determinism
20%
SARS Coronavirus
20%
Focal Adhesion
18%
RNA
18%
RNA Polymerase II
16%
Survival Rate
14%
Comorbidity
13%
PNPLA3
13%
Binding Domain
12%
Receptor Binding
12%
Programmed Cell Death
10%
Ubiquitination
10%
Cell Migration
9%
Medicine and Dentistry
Retrospective Cohort Study
50%
Lung Function
50%
Bone Density
48%
Hyperuricemia
48%
Liver Disease
48%
Hyperlipidemia
48%
Statin
48%
Neutron Capture Therapy
48%
Tyrosine-Kinase Inhibitor
34%
Tumor Spheroid
31%
Cancer Cell
30%
Pancreas Tumor
29%
Lung
28%
Non Small Cell Lung Cancer
28%
In Vitro
24%
Immunogenicity
24%
Pancreatic Cancer
24%
Survival Analysis
24%
Protein Tyrosine Kinase
24%
Growth Factor Receptor
24%
Alisertib
24%
In Silico
24%
Mesenchymal-Epithelial Transition
24%
Adenocarcinoma
24%
Reactogenicity
24%
Adjuvant Chemotherapy
24%
Squamous Cell Carcinoma
24%
Angioleiomyoma
24%
Cabozantinib
24%
Ferroptosis
24%
Triglyceride-Glucose Index
24%
Metabolic Dysfunction-Associated Steatotic Liver Disease
24%
Cancer Risk
24%
Obstructive Airway Disease
24%
Prospective Cohort Study
24%
Insulin Resistance
20%
Single Nucleotide Polymorphism
19%
Hazard Ratio
17%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Overall Survival
12%
Non-Small Cell Lung Cancer
12%
Aurora A Kinase
12%
Cancer
11%
Spirometry
11%
Fibroblast
10%
Neoplasm
9%
Comorbidity
9%
Pancreas Cancer
9%
Failure Free Survival
9%
Fatty Liver
8%
